Exelixis | EXEL - Current Liabilities


Exelixis reported $361.93M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 361.44M 55.91M Jun/2026
Agios Pharmaceuticals USD 70.22M 11.37M Jun/2026
Akebia Therapeutics USD 160.86M 13.02M Jun/2026
Amgen USD 25.5B 547M Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
Bayer EUR 32.27B 1.19B Jun/2026
BioMarin Pharmaceutical USD 1.66B 870.84M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Cytokinetics USD 181.43M 17.76M Jun/2026
Eisai JPY 393.64B 53.39B Jun/2026
Eli Lilly USD 47.74B 11.11B Jun/2026
Exelixis USD 361.93M 9.05M Jun/2026
Genmab DKK 1.14B 38M Jun/2026
Glaxosmithkline GBP 22.43B 6.39B Mar/2026
Incyte USD 1.31B 177.55M Jun/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
MacroGenics USD 108.82M 12.88M Jun/2026
Merck USD 27.73B 786M Jun/2026
Moderna USD 2.53B 139M Jun/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Novartis USD 31.75B 374M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Sanofi EUR 30.01B 1.66B Mar/2026
Takeda JPY 2.76T 335.02B Jun/2026
Ultragenyx Pharmaceutical USD 351M 26M Jun/2026
Xencor USD 81.86M 8.41M Jun/2026